China: A New Era of Innovation in Drug Development
Author: Sara Gambrill
Volume discounts and licensing opportunities are available. For more information, call (866) 219-3440,
option 1, or e-mail sales@centerwatch.com.
In the latest edition from our Clinical Trials Special Report Series, we break down
China’s clinical trials landscape and analyze the government investments that are making
the country more attractive for inclusion in global drug development programs of pharma
companies of all sizes.
Key features include:
- Government initiatives driving growth
- Benefit analysis for domestic and global pharma
- Big Pharma plans for the region
- Drug development pipeline
- Select list of 100+ CROs
- Charts and figures
Recommended for:
- Biotech and pharmaceutical companies seeking information on growth and challenges
in China’s clinical trials market
- Investment firms covering the life sciences industry in emerging markets
- CROs conducting business in China
Other titles in this series:
Purchase a copy of this important resource and make China part of your global plans!